Literature DB >> 26001510

Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: Result of the MADIT-RIT efficacy analysis.

Valentina Kutyifa1, James P Daubert2, Brian Olshansky3, David T Huang1, Claire Zhang1, Anne-Christine H Ruwald1, Scott McNitt1, Wojciech Zareba1, Arthur J Moss1, Claudio Schuger4.   

Abstract

BACKGROUND: Data on inappropriate implantable cardioverter-defibrillator (ICD) therapy and effects of programming by heart rate are lacking.
OBJECTIVE: We aimed to characterize inappropriate ICD therapy and assess the effects of novel programming by heart rate.
METHODS: Incidence and causes of inappropriate therapy by heart rate range (below or above 200 bpm) were assessed. Predictors of inappropriate therapy and effects of programming by heart rate were evaluated with multivariate Cox regression models. Crossovers were excluded.
RESULTS: Inappropriate therapy occurred in 9.2% of the total patient population, with 19% of patients randomized to study arm A, 3.6% in arm B, and 4.7% in arm C. Inappropriate therapies <200 bpm were attributable to supraventricular tachycardia (SVT)/sinus tachycardia (78%) or atrial fibrillation/flutter (20%). Inappropriate therapy ≥200 bpm occurred because of SVT (47%), atrial fibrillation/flutter (41%), or electromagnetic interference (13%). Conventional ICD programming was associated with more inappropriate therapy <200 bpm than high-rate or delayed therapy, as were younger age, history of atrial arrhythmia, advanced New York Heart Association functional class, ICD versus cardiac resynchronization therapy with defibrillator, and absence of diabetes. High-rate and long-delay therapy significantly reduced the risk of inappropriate therapy in the <200 bpm range. Long delay was associated with further reduction of fast (≥200 bpm) inappropriate therapy (P = .032) and a reduction in subsequent inappropriate episodes (P = .006).
CONCLUSION: In MADIT-RIT, inappropriate ICD therapy is most frequent at rates below 200 bpm and can be predicted, and effectively prevented, with high-rate cutoff programming. Long-delay therapy effectively reduces fast inappropriate therapy ≥200 bpm and subsequent events. [ CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov/ct2/show/NCT00947310].
Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-rate cutoff; Implantable cardioverter-defibrillator; Long delay; Predictors; Programming; Subsequent inappropriate therapy; Therapy

Mesh:

Year:  2015        PMID: 26001510     DOI: 10.1016/j.hrthm.2015.05.021

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  3 in total

1.  Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients.

Authors:  Yusuke Hayashi; Masahiko Takagi; Jun Kakihara; Shogo Sakamoto; Atsushi Doi; Kenichi Sugioka; Akihisa Hanatani; Minoru Yoshiyama
Journal:  Heart Vessels       Date:  2016-06-03       Impact factor: 2.037

2.  A real-world experience of subcutaneous and transvenous implantable cardiac defibrillators-comparison with the PRAETORIAN study.

Authors:  Dibbendhu Khanra; Abdul Hamid; Peysh Patel; John Tomson; Ahmed Abdalla; Nasrin Khan; Rory Dowd; Nakul Chandan; Christopher Osagie; Tomilola Jinadu; Selvakumar Velu; Anita Arya; Charles Spencer; Craig Barr; Sanjiv Petkar
Journal:  J Arrhythm       Date:  2022-02-21

3.  Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.

Authors:  Robert T Greenlee; Alan S Go; Pamela N Peterson; Andrea E Cassidy-Bushrow; Charles Gaber; Romel Garcia-Montilla; Karen A Glenn; Nigel Gupta; Jerry H Gurwitz; Stephen C Hammill; John J Hayes; Alan Kadish; David J Magid; David D McManus; Deborah Multerer; J David Powers; Liza M Reifler; Kristi Reynolds; Claudio Schuger; Param P Sharma; David H Smith; Mary Suits; Sue Hee Sung; Paul D Varosy; Humberto J Vidaillet; Frederick A Masoudi
Journal:  J Am Heart Assoc       Date:  2018-03-26       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.